AUDIT OF USFDA APPROVALS FOR 2022 FROM THE PERSPECTIVE OF INNOVATION
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i7.47509Keywords:
Innovative research, New Molecular Entities, USFDA, Healthcare ProfessionalsAbstract
Objectives: The United States of America (USA) is having a unique place in global innovation within the health-care sector due to the presence of a large number of research-oriented biopharmaceutical companies, contract research organizations, and government research agencies. The aim of this study was to analyze the U.S. Food and Drug Administration (USFDA) approvals for 2022 to increase the awareness among health-care professionals for better clinical decisions.
Methods: This was an observational study conducted using online database of USFDA which is accessible freely by the public. The USFDA approvals for 2022 were assessed for new molecular entities (NMEs) including their source and therapeutic area, new indications (NIs) of previously approved drugs, new label extensions (NLEs) of previously approved drugs, new routes of administration (NRAs) of previously approved drugs, and new dosage forms (NDFs) of previously approved drugs. The data obtained were arranged in the tabular form using Microsoft Office Excel 2007. Descriptive statistics was used for analysis.
Results: Out of 118 USFDA approvals considered for this study, 25.4% of them were given for NMEs, 27.9% approvals were given for NIs, 33.8% approvals were given for NLEs, 6.7% approvals were given for NRAs, and the remaining 5.9% approvals were given for NDFs. 14 out of 30 NMEs were biologicals and 43.3% of NMEs were indicated for different types of cancer.
Conclusion: The USFDA continued to adopt several approaches such as Fast Track process, breakthrough therapy process, accelerated approval process, and priority review process to encourage the research-based biopharmaceutical companies involved in the development of therapeutic options for patients suffering from common as well as rare diseases. More emphasis was given to the approvals of anticancer drugs given the limited options available to treat the cancer in advanced or metastatic stages. However, a lack of discovery and development of antimicrobials with novel mechanism of actions to combat resistance is a cause of concern.
Downloads
References
World Health Organization (WHO). Clinical Trials. Available from: https://www.who.int/news-room/questions-and-answers/item/clinical-trials [Last accessed on 2023 Jan 01].
Central Drugs Standard Control Organization (CDSCO). NDCT Rules 2019. Available from: https://cdsco.gov.in/opencms/export/sites/ cdsco_web/pdf-documents/newdrugs_ctrules_2019.pdf [Last accessed on 2023 Jan 01].
US Food and Drug Administration (FDA). Hemgenix. Available from: https://www.drugs.com/newdrugs/fda-approves-hemgenix-etranacogene-dezaparvovec-drlb-gene-therapy-hemophilia-b-5931. html [Last accessed on 2023 Jan 01].
US Food and Drug Administration (FDA). Tzield. Available from: https://www.drugs.com/newdrugs/fda-approves-tzield-teplizumab-mzwv-delay-onset-stage-3-type-1-diabetes-5929.html [Last accessed on 2023 Jan 01].
US National Library of Medicine. Clinical Trials. Available from: https://clinicaltrials.gov [Last accessed on 2023 Jan 01].
US Food and Drug Administration (FDA). CDER’s New Molecular Entities and New Therapeutic Biological Products. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/ new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products [Last accessed on 2023 Jan 01].
US Food and Drug Administration (FDA). CBER’s; 2022. Biological Approvals. Available from: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year [Last accessed on 2023 Jan 01].
US Food and Drug Administration (FDA). Available from: https:// www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review [Last accessed on 2023 Jan 01].
The Importance of having a Primary Care Doctor. Available from: https://my.clevelandclinic.org/health/articles/16507-the-importance-of-having-a-primary-care-doctor [Last accessed on 2023 Jan 01].
Batta A, Kalra BS, Khirasaria R. Trends in FDA drug approvals over last 2 decades: An observational study. J Family Med Prim Care 2020;9:105-14. doi: 10.4103/jfmpc.jfmpc_578_19, PMID 32110574
De la Torre BG, Albericio F. The pharmaceutical industry in 2021. An analysis of FDA drug approvals from the perspective of molecules. Molecules 2022;27:1075. doi: 10.3390/molecules27031075
Shukla KA, Mehani R, Jain S, Maqsood S. Analysis of FDA novel drug approvals. Biomed Pharmacol J 2021;14:225-33.
Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83. doi: 10.1038/nrd1468, PMID 15286734
Introduction to Cystic Fibrosis. Available from: https://www.cff.org/ intro-cf [Last accessed on 2023 Jan 01].
Jain KK. An overview of drug delivery systems. Methods Mol Biol 2020;2059:1-54. doi: 10.1007/978-1-4939-9798-5_1, PMID 31435914
Galande AD, Khurana NA, Mutalik S. Pediatric dosage forms-challenges and recent developments: A critical review. J App Pharm Sci 2020;10:155-66. doi: 10.7324/JAPS.2020.10718
Published
How to Cite
Issue
Section
Copyright (c) 2023 RAJESH DASARAJU, PATIL BAPUGOUDA, MANOHAR BENDE, ASHUTOSH MANGALGIRI, THEJASWINI MUPPALA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
